Serina Therapeutics Inc (SER) Q1 2025 Earnings Report

Serina Therapeutics reported its QQ1 2025 results with no material revenue and a continued burn driven by R&D and general & administrative expenses. Total operating expenses for the quarter were $5.858 million, comprised of $2.951 million in R&D and $2.907 million in G&A, yielding an EBITDA of -$4.805 million and an operating loss of -$5.858 million. Net income was -$4.813 million, or -$0.49 per share on 9.756 million weighted-average shares, reflecting ongoing pre-commercial development activity across the company’s pipeline. Cash burn from operating activities amounted to -$4.322 million during QQ1 2025, while financing activity provided a cash inflow of $4.917 million from common stock issuance, resulting in a modest net cash increase of $0.595 million and ending cash of $4.267 million.

The balance sheet shows a tight but improving liquidity position for a pre-revenue biotech: total assets of $6.731 million vs. total liabilities of $5.172 million, and stockholders’ equity of $1.701 million alongside a substantial accumulated deficit of $49.131 million. The company also reports net debt of approximately -$4.04 million, reflecting cash on hand exceeding debt obligations. Management commentary is not included in the provided transcript data, but the quarter’s performance aligns with the typical early-stage biotech profile: meaningful R&D investment, near-term cash burn, and a reliance on equity financing to fund pipeline activities.

From a medical and strategic perspective, Serina continues to advance a multi-product strategy focused on SER-252 (POZ conjugate for Parkinson’s disease) and SER-227 (long-acting pain relief), among other programs. While there is no revenue yet, the company’s trajectory will hinge on upcoming pipeline milestones, IND/clinical progression, and potential partnerships or licensing discussions that could convert scientific progress into value inflection points for investors.